Renaissance Technologies's PTCT Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 927,300 shares of PTC Therapeutics, Inc. (PTCT) worth $56.91 M, representing 0.08% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in PTCT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2016, adding 882,800 shares. Largest reduction occurred in Q2 2016, reducing 846,800 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +21,600 | New Buy | 21,600 | $26.16 |
| Q3 2014 | -21,600 | Sold Out | 21,600 | $0.00 |
| Q3 2015 | +65,900 | New Buy | 65,900 | $26.71 |
| Q4 2015 | -65,900 | Sold Out | 65,900 | $0.00 |
| Q1 2016 | +948,700 | New Buy | 948,700 | $6.44 |
| Q2 2016 | -846,800 | Reduce 89.26% | 101,900 | $7.02 |
| Q3 2016 | +450,800 | Add 442.39% | 552,700 | $14.01 |
| Q4 2016 | -552,700 | Sold Out | 552,700 | $0.00 |
| Q4 2017 | +226,600 | New Buy | 226,600 | $16.68 |
| Q1 2018 | -7,400 | Reduce 3.27% | 219,200 | $27.06 |
| Q2 2018 | -219,200 | Sold Out | 219,200 | $0.00 |
| Q3 2018 | +282,600 | New Buy | 282,600 | $47.00 |
| Q4 2018 | +740,100 | Add 261.89% | 1.02 M | $34.32 |
| Q1 2019 | -115,400 | Reduce 11.28% | 907,300 | $37.64 |
| Q2 2019 | -538,240 | Reduce 59.32% | 369,060 | $45.00 |
| Q3 2019 | -238,760 | Reduce 64.69% | 130,300 | $33.82 |
| Q4 2019 | +183,600 | Add 140.91% | 313,900 | $48.03 |
| Q1 2020 | +65,500 | Add 20.87% | 379,400 | $44.61 |
| Q2 2020 | -374,200 | Reduce 98.63% | 5,200 | $50.77 |
| Q3 2020 | -5,200 | Sold Out | 5,200 | $0.00 |
| Q1 2021 | +191,200 | New Buy | 191,200 | $47.35 |
| Q2 2021 | +13,810 | Add 7.22% | 205,010 | $42.27 |
| Q3 2021 | -123,410 | Reduce 60.20% | 81,600 | $37.21 |
| Q4 2021 | -59,600 | Reduce 73.04% | 22,000 | $39.82 |
| Q1 2022 | -22,000 | Sold Out | 22,000 | $0.00 |
| Q3 2022 | +5,600 | New Buy | 5,600 | $50.18 |
| Q4 2022 | -5,600 | Sold Out | 5,600 | $0.00 |
| Q3 2023 | +234,600 | New Buy | 234,600 | $22.41 |
| Q4 2023 | +388,300 | Add 165.52% | 622,900 | $27.56 |
| Q1 2024 | +138,500 | Add 22.23% | 761,400 | $29.09 |
| Q2 2024 | +56,700 | Add 7.45% | 818,100 | $30.58 |
| Q3 2024 | -279,900 | Reduce 34.21% | 538,200 | $37.10 |
| Q4 2024 | +114,900 | Add 21.35% | 653,100 | $45.14 |
| Q1 2025 | +17,100 | Add 2.62% | 670,200 | $50.96 |
| Q2 2025 | +293,100 | Add 43.73% | 963,300 | $48.84 |
| Q3 2025 | -36,000 | Reduce 3.74% | 927,300 | $61.37 |
Renaissance Technologies's PTC Therapeutics Investment FAQs
Renaissance Technologies first purchased PTC Therapeutics, Inc. (PTCT) in Q2 2014, acquiring 21,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held PTC Therapeutics, Inc. (PTCT) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2016, adding 948,700 shares worth $6.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 927,300 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $56.91 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.08% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in PTC Therapeutics, Inc. (PTCT) was 1,022,700 shares, as reported at the end of Q4 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.